Monday, November 13, 2006
Health Care Glut
Pharmas are going to be the main whipping post for the democrate in congress but with just a slim majority and President Bush still in the White House with his veto power, little action will be taken. Right now, Pharmas have experienced a downturn since last Tuesday. Wall St. is basically pricing in a slim chance of some pricing controls being passed. For now, the sectors outlook looks as bright as ever.
My position in Genentech will not be altered. At $81 a share, it is trading at 30x forward earnings; not cheap by any means but way off hisotorical P/e's. This might present a possible buying opportunity for additional shares for a company growing at a 20% rate.
IV Calc
![]() | |
![]() ![]() |
|
![]() | |
![]() ![]() ![]() ![]() ![]() ![]() |
|
![]() |
|
|
No comments:
Post a Comment